Irbesartan + Hidroclorotiazida Azevedos

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan + Hidroclorotiazida Azevedos, is an angiotensin II receptor blocker and thiazide diuretic presented as a tablet for oral use. It treats hypertension in adult patients, helping to lower blood pressure through combined vasodilation and diuresis.

GNH USA supplies Irbesartan + Hidroclorotiazida Azevedos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage conditions within the cardiovascular and renal disease spectrum.

- Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension. - Diabetic nephropathy: helps reduce progression of kidney damage in adults with type 2 diabetes. - Heart failure (adjunct): may assist in fluid management when combined with other therapies.

The combination may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination or electrolyte imbalance (e.g., low potassium)

Serious or Rare Side Effects: - Severe hypotension - Hyperkalemia or significant electrolyte disturbances - Angioedema or severe allergic reactions

Before prescribing Irbesartan/Hydrochlorothiazide, clinicians should consider several safety measures.

- Monitor blood pressure: adjust therapy if hypotension occurs. - Check electrolytes: especially potassium and sodium levels during treatment. - Assess renal function: avoid use in severe renal impairment without close monitoring. - Use caution in pregnancy: drug is classified as Category D and may harm the fetus. - Discontinue if angioedema develops: seek immediate medical attention. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Irbesartan/Hydrochlorothiazide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: additive effects on potassium and renal function. - Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise irbesartan plasma concentrations. - Other antihypertensives (beta‑blockers, calcium channel blockers): may cause additive blood‑pressure lowering.